Literature DB >> 11521173

NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors.

K Braun1, J Rettinger, M Ganso, M Kassack, C Hildebrandt, H Ullmann, P Nickel, G Schmalzing, G Lambrecht.   

Abstract

Antagonistic effects of the novel suramin analogue 4,4',4",4"'-(carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid (NF449) were studied on contractions of the rat vas deferens elicited by alpha,beta-methylene ATP (alphabetameATP; mediated by P2X1 receptors), contractions of the guinea-pig ileal longitudinal smooth muscle elicited by alphabetameATP (mediated by P2X3 receptors) or adenosine 5'-O-(2-thiodiphosphate) (ADPbetaS; mediated by P2Y1 receptors), ATP-induced increases of [Ca2+]i in human embryonic kidney (HEK) 293 cells (mediated by P2Y2 receptors), inward currents evoked by ATP in follicle cell-free Xenopus laevis oocytes expressing rP2X1 or rP2X3 receptors and degradation of ATP by ecto-nucleotidases in folliculated Xenopus laevis oocytes. In addition, NF449 was examined for its P2 receptor specificity in rat vas deferens (alpha1A-adrenoceptors) and guinea-pig ileum (histamine H1 and muscarinic M3 receptors). At native (pIC50=7.15) and recombinant (pIC50=9.54) P2X1 receptors, NF449 was a highly potent antagonist. The P2X3 receptors present in guinea-pig ileum (pIC50=5.04) or expressed in oocytes (pIC50 approximately 5.6) were much less sensitive for NF449. It also was a very weak antagonist at P2Y1 receptors in guinea-pig ileum (pIC50=4.85) and P2Y2 receptors in HEK 293 cells (pIC50=3.86), and showed very low inhibitory potency on ecto-nucleotidases (pIC50<3.5). NF449 (100 microM) did not interact with alpha1A-adrenoceptors or histamine H1 and muscarinic M3 receptors. Thus, the antagonism by NF449 is highly specific for P2 receptors. In conclusion, the subnanomolar potency at rP2X1 receptors and the rank order of potency, P2X1 >> P2X3 > P2Y1 > P2Y2 > ecto-nucleotidases, make NF449 unique among the P2 receptor antagonists reported to date. NF449 may fill the long-standing need for a P2X1-selective radioligand.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11521173     DOI: 10.1007/s002100100463

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  20 in total

Review 1.  Molecular recognition at purine and pyrimidine nucleotide (P2) receptors.

Authors:  Kenneth A Jacobson; Stefano Costanzi; Michihiro Ohno; Bhalchandra V Joshi; Pedro Besada; Bin Xu; Susanna Tchilibon
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

Review 2.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

Review 3.  Insights into the channel gating of P2X receptors from structures, dynamics and small molecules.

Authors:  Jin Wang; Ye Yu
Journal:  Acta Pharmacol Sin       Date:  2016-01       Impact factor: 6.150

4.  The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range.

Authors:  Susanne Horner; Kirsten Menke; Caren Hildebrandt; Matthias U Kassack; Peter Nickel; Heiko Ullmann; Martyn P Mahaut-Smith; Günter Lambrecht
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-09-13       Impact factor: 3.000

Review 5.  Mechanisms for inhibition of P2 receptors signaling in neural cells.

Authors:  Fernando A González; Gary A Weisman; Laurie Erb; Cheikh I Seye; Grace Y Sun; Betty Velázquez; Melvin Hernández-Pérez; Nataliya E Chorna
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

Review 6.  Activation and regulation of purinergic P2X receptor channels.

Authors:  Claudio Coddou; Zonghe Yan; Tomas Obsil; J Pablo Huidobro-Toro; Stanko S Stojilkovic
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

7.  Chronic loss of noradrenergic tone produces β-arrestin2-mediated cocaine hypersensitivity and alters cellular D2 responses in the nucleus accumbens.

Authors:  Meriem Gaval-Cruz; Richard B Goertz; Daniel J Puttick; Dawn E Bowles; Rebecca C Meyer; Randy A Hall; Daijin Ko; Carlos A Paladini; David Weinshenker
Journal:  Addict Biol       Date:  2014-08-13       Impact factor: 4.280

8.  NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.

Authors:  Pavel Krejci; Shunichi Murakami; Jirina Prochazkova; Lukas Trantirek; Katarina Chlebova; Zhufeng Ouyang; Anie Aklian; Jiri Smutny; Vitezslav Bryja; Alois Kozubik; William R Wilcox
Journal:  J Biol Chem       Date:  2010-05-03       Impact factor: 5.157

9.  Vascular smooth muscle cells from small human omental arteries express P2X1 and P2X4 receptor subunits.

Authors:  Claire M Nichols; Oleksandr V Povstyan; Anthony P Albert; Dmitry V Gordienko; Omar Khan; Georgios Vasilikostas; Teck K Khong; Andrew Wan; Marcus Reddy; Maksym I Harhun
Journal:  Purinergic Signal       Date:  2014-05-22       Impact factor: 3.765

10.  P2X purinergic receptor-mediated ionic current in cardiac myocytes of calsequestrin model of cardiomyopathy: implications for the treatment of heart failure.

Authors:  Jian-Bing Shen; Chunxia Cronin; Dmitry Sonin; Bhalchandra V Joshi; Maria Gongora Nieto; David Harrison; Kenneth A Jacobson; Bruce T Liang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-10-13       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.